Bromelain and Escin in the Reduction of Postoperative Sequelae in Periodontal and Implant Surgery
Bromelain and Escin in the Reduction of Postoperative Sequelae in Periodontal and Implant Surgery
A randomized clinical trial will be performed in parallel, placebo controlled, double-blind
 to evaluate the effectiveness of the association Bromelina and Horse-chestnut (titrated in
 escin) (Noflogo®, Mavenpharma s.r.l., Rome, Italy) in the management of post trauma-surgery
 following surgery periodontal and implant surgery.
At least 50 volunteers between the ages of 18 and 50, will be enlisted, with the need to
 perform one of the interventions described above and that fall within the criteria of
 inclusion.

 The study will be carried out in accordance with the Helsinki Declaration on In Vivo Studies
 and will be initiated with the approval of the Internal Review Board of the University of
 L'Aquila.

 The protocol follows the guidelines of the CONSORT Statement for parallel studies and will be
 recorded on the data base clinicaltrials.gov.
Inclusion Criteria: To be treated patients will not have to show signs of gingival
 inflammation. Patients undergoing periodontal surgery should have completed non-surgical
 causal therapy and presented FMBS and FMPS values of 20%.

 Exclusion Criteria:All subjects with positive anamensis for relevant systemic pathologies
 (renal, cardiovascular, hepatic, infectious, neoplastic and diabetological), treatment with
 anti-inflammatory and/or antibiotics in the two weeks preceding the start of the trial will
 be excluded, history of allergy to one or more components of the medication to be tested,
 pregnant women.